EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Botanix Pharmaceuticals Ltd (BOT) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Botanix Pharmaceuticals Ltd A$0.02, price A$0.02, upside -17.9%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · AU · ISIN AU000000BOT2

BP Botanix Pharmaceuticals Ltd logo Thin data Sep 24, 2026

Botanix Pharmaceuticals Ltd

BOT · AU

Weak valuationQuality is weak on top of the rich price.

!Fair value A$0.0156 · Overvalued (−18%)
!Quality 25/100
!Weak Growth (revenue 5y −5.2 %/yr)
!Low debt · negative free cash flow
!Mixed vs. peers (4/8)
!Narrow moat 9/100
!Insider activity 45/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 9 out of 100
Watch Botanix Pharmaceuticals Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.5200 A$0.0180 Fair Value A$0.0156 Jul 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range A$0.0180 – A$0.5200 · fair‑value band A$0.0141 – A$0.0156 · the A$0.0190 price screens above the A$0.0156 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.

Follow Botanix Pharmaceuticals in your weekly email

Every Wednesday you see whether Botanix Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older.

Show more

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis. The company was incorporated in 1984 and is based in Melbourne, Australia.

Stock analysis

Botanix Pharmaceuticals Ltd (BOT) currently trades at A$0.0190, while our model-based Fair Value estimate is A$0.0156, implying the stock looks roughly 21.8% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: A$0.0141 (bear) to A$0.0156 (bull), the price of A$0.0190 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Botanix Pharmaceuticals Ltd reported revenue of A$5.8M in FY2025 versus A$6.9M in FY2021, a compound −4.2%/yr. Reported net income was −A$86.4M in FY2025.

Key figures

Market cap A$65.3M (≈ $45.8M) · P/S ratio 2.98 · EPS (TTM) A$−0.0500 · Return on equity −121% · Return on assets (EBIT) −57.7% · Operating margin −204% · Revenue growth (YoY) +42.7% · Free cash flow −A$78.9M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (low confidence).

What moves the price

The share trades about 89% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −18%, BOT screens richer than that median.

Fair Value models

Bear A$0.0141 Fair Value A$0.0156 Bull A$0.0156
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) A$0.0100 A$0.0200 A$0.0300 52
All 1 models by family
Asset-Based
NCAV (Graham) A$0.0100 A$0.0200 A$0.0300 52

Open the full fair value analysis →

Notify me when BOT reaches fair value

Put BOT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 25/100

Of which business quality 29 · Market factors (momentum, volatility) 16

Profitability 1
Margins and returns on capital today
Quality Growth 74
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 69
Balance sheet, leverage, solvency risk
Investment 28
Disciplined investing over empire-building
Low Volatility 36
Calm price path (market factor)
Momentum 13
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+861.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
Start year 2020 (pandemic). Over 10 years: +63.2% a year
Revenue growth 36 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−389.5% (2020) → −1,395.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

BOT screens 22% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Botanix Pharmaceuticals Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −18% · Above median
Profitability
Return on assets −53% · Bottom 25%
Growth and dividend
Revenue growth 43% · Top 25%
Balance sheet
Debt / equity 0.27× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.56× · Cheapest 25%
P/S (TTM) 2.09× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)9 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)86 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $522.38 $574.62 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Botanix Pharmaceuticals Ltd · Fair Value
A$0.0156 −22%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Botanix Pharmaceuticals Ltd Fair Value". https://www.fairvalue-calculator.com/stock/BOT

Frequently asked questions

Is Botanix Pharmaceuticals Ltd (BOT) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of A$0.0156 versus a price of A$0.0190, about −18% upside (overvalued).
What is the fair value of BOT?
Our model-based fair value for Botanix Pharmaceuticals Ltd is A$0.0156 (as of Sep 24, 2026), built from audited fundamentals. The current price: A$0.0190.
What is the quality score of BOT?
Botanix Pharmaceuticals Ltd has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Botanix Pharmaceuticals Ltd (BOT)?
Our model-based price target is the fair value of A$0.0156 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario A$0.0141, optimistic scenario A$0.0156. It is a calculation from audited fundamentals, not an analyst target.
What is the Botanix Pharmaceuticals Ltd stock forecast for 2026?
Our models put fair value at A$0.0156, about −18% upside versus a price of A$0.0190 (overvalued). Cautious scenario A$0.0141, optimistic scenario A$0.0156. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Botanix Pharmaceuticals Ltd (BOT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Botanix Pharmaceuticals Ltd it is A$0.0156 per share (as of Sep 24, 2026), against a price of A$0.0190. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Botanix Pharmaceuticals Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, BOT trades above its calculated fair value: price A$0.0190, fair value A$0.0156, a gap of about −18% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BOT?
No. The price is what the market pays today (A$0.0190); the fair value is what the company's own numbers justify (A$0.0156). For Botanix Pharmaceuticals Ltd the two are A$0.0034 per share apart. That gap is exactly why we show both numbers side by side.
How much is Botanix Pharmaceuticals Ltd worth?
The market values Botanix Pharmaceuticals Ltd at about A$65.3M (market capitalisation, as of Sep 24, 2026). Per share that is A$0.0190; our models calculate a fair value of A$0.0156 per share.
What do the bullish and bearish scenarios say about BOT?
Our models span a range for Botanix Pharmaceuticals Ltd: cautious scenario A$0.0141, base A$0.0156, optimistic A$0.0156 per share (as of Sep 24, 2026, price A$0.0190). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Botanix Pharmaceuticals Ltd (BOT)?
Balance-sheet figures for Botanix Pharmaceuticals Ltd (as of Sep 24, 2026): return on equity −121.1%, debt of 0.27 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is BOT from its 52-week high?
Botanix Pharmaceuticals Ltd trades at A$0.0190, about 89% below its 52-week high of A$0.1700 and 6% above the low of A$0.0180 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0156 is for.
Which stocks are comparable to Botanix Pharmaceuticals Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Botanix Pharmaceuticals Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price A$0.0190, calculated fair value A$0.0156 (−18%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BOT calculated?
We run Botanix Pharmaceuticals Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0156, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Botanix Pharmaceuticals Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Botanix Pharmaceuticals Ltd (BOT)?
The closing price on Sep 24, 2026 was A$0.0190. Our model-based fair value is A$0.0156, about −18% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Botanix Pharmaceuticals Ltd right now?
The price sits above even our optimistic bull case (A$0.0156). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band (A$0.0141 to A$0.0156), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Botanix Pharmaceuticals Ltd

How large is the market capitalisation of Botanix Pharmaceuticals Ltd (BOT)?
The market capitalisation of Botanix Pharmaceuticals Ltd is A$65.3M (≈ $45.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Botanix Pharmaceuticals Ltd (BOT)?
The price-to-sales ratio of Botanix Pharmaceuticals Ltd is 2.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Botanix Pharmaceuticals Ltd (BOT)?
Earnings per share at Botanix Pharmaceuticals Ltd are A$−0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Botanix Pharmaceuticals Ltd (BOT)?
The return on equity (ROE) of Botanix Pharmaceuticals Ltd is −121% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Botanix Pharmaceuticals Ltd (BOT)?
On an EBIT basis the return on assets of Botanix Pharmaceuticals Ltd is −57.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Botanix Pharmaceuticals Ltd (BOT)?
The operating margin of Botanix Pharmaceuticals Ltd is −204% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Botanix Pharmaceuticals Ltd (BOT)?
Revenue at Botanix Pharmaceuticals Ltd is growing +42.7% versus a year earlier (3y avg +28.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Botanix Pharmaceuticals Ltd (BOT) generate?
The free cash flow of Botanix Pharmaceuticals Ltd is −A$78.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Botanix Pharmaceuticals Ltd (BOT) hold?
Botanix Pharmaceuticals Ltd holds more cash than debt, A$32.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Botanix Pharmaceuticals Ltd in the live analysis

One click puts Botanix Pharmaceuticals Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.